Bausch Health Companies Inc (BHC) Gets a Hold Rating from BMO Capital


BMO Capital analyst Gary Nachman reiterated a Hold rating on Bausch Health Companies Inc (BHC) on November 11 and set a price target of $26. The company’s shares closed yesterday at $26.63, close to its 52-week high of $28.45.

According to TipRanks.com, Nachman is a 4-star analyst with an average return of 6.8% and a 50.8% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Sienna Biopharmaceuticals Inc, Aquestive Therapeutics Inc, and Amphastar Pharmaceuticals.

Currently, the analyst consensus on Bausch Health Companies Inc is a Moderate Buy with an average price target of $28.78, implying an 8.1% upside from current levels. In a report issued on November 7, RBC Capital also maintained a Hold rating on the stock with a $31 price target.

.

See today’s analyst top recommended stocks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts